|
[1] Bernstein J. Polymorphism-A perspective[J]. Crystal Growth Des, 2011, 11: 632-650
[2] Cabri W, Ghetti P, Alpegiani M,et al. Cefdinir: A comparative study of anhydrous vs. monohydrate form: Microstructure and tabletting behavior[J]. Eur J Pharm Biopharm, 2006, 64: 212-221
[3] Kawashima Y, Niwa T, Takeuchi H, et al. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques[J]. J Pharm Sci, 1991, 80: 472-478
[4] Allen P, Rahn P, Sarapu A, et al. Physical characterization of erythromycin: Anhydrate, monohydrate, and dihydrate crystalline solids[J]. J Pharm Sci, 1978, 67: 1 087-1 093
[5] Henwood S, Liebenberg W, Tiedt L, et al. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates[J]. Drug Dev Ind Pharm, 2001, 27: 1 017-1 030
[6] Hilfiker R. Polymorphism in the pharmaceutical industry[M]. Weinheim: Hilfiker R, 2006
[7] Tian F, Qu H, Zimmermann A, et al. Factors affecting crystallization of hydrates[J]. J Pharm Pharmacol, 2010, 62: 1 534-1 546
[8] Zimmermann A, Tian F, Diego H, et al. Structural characterization and dehydration behavior of siramesine hydrochloride[J]. J Pharm Sci, 2009, 98: 3 596-3 607
[9] Sun C, Zhou D, Grant D,et al. Theophylline monohydrate[J]. Acta Crystallorg Sect E, 2002, 58: 368-370
[10] Gossman W, Wilson S, Oldfield E. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures[J]. Acta Crystallogr C, 2003, 59: 33-36
[11] Briggs C, Harasawa K, Ichikawa S, et al. Crystalline[R-(R*,R*)]-2-(4-dfluorophenyl)-β,α-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-1-heptanoic acid hemi calcium salt (Atorvastatin): US, 005969156[P]. 1999-10-19
[12] Giron D, Goldbronn C, Mutz M, et al. Solid state characterizations of pharmaceutical hydrates[J]. J Therm Anal Calorim, 2002, 68: 453-465
[13] 王博超. 盐酸多奈哌齐结晶过程研究[D]. 天津: 天津大学, 2008
|
2016, Vol. 33 
